MUFJ
Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: Medtech could add A$18 billion to Australian economy.

The Commonwealth Scientific and Industrial Research Organisation’s new medical technologies and pharmaceuticals roadmap sets out a path for how Australia could become an important player in medical technologies and pharmaceuticals, which is expected to grow to almost A$3 trillion (US$2.3 trillion) globally by 2025.

“The symbiosis of digital with physical creates new individualised medtech solutions, from 3D printed replacement body parts to personalised brain cancer treatments, growing this sector will save lives in Australia and around the world,” CSIRO chief executive Larry Marshall said.

With Australia’s spending on healthcare expected to almost double to 16% of GDP by 2040, a renewed focus on the successful translation of excellent science to cheaper and more effective health and medical solutions is a national priority.

“The medical technologies and pharmaceuticals (MTP) roadmap shows how Australia can use excellent science to navigate the challenges associated with an ageing population effectively, while also capitalising on global opportunities,” Marshall said.

The MTP sector is expected to be worth almost A$3 trillion globally by 2025 with a projected annual growth rate of 5.6%.

MTPConnect, the industry innovation growth centre for the sector, has estimated in its sector competitiveness plan that Australia could create an additional 28,000 jobs by 2025 and add an additional A$18 billion to the economy over this period if measures outlined in the CSIRO roadmap were adopted.

The roadmap states that the MTP industry will serve as an important economic driver in the future as the sector grows rapidly across the globe due to ageing populations, unprecedented technological advancements and growing health sectors in the developing world.

It outlines four main areas that Australia could capitalise on, based on global trends and its existing advantages: smart devices, implants and bionics; accelerated pharmaceutical development; manufacturing high-value pharmaceuticals; and diagnostics, informatics products and services.

 “Australia is acknowledged as a world leader in the medtech, biotech and pharma sector due to our vibrant research environment,” MTPConnect chief executive Sue MacLeman said.

“It is now time for us to come together as a sector to harness our research capabilities, work to our strengths and produce an internationally renowned commercialisation ecosystem to secure the economic and physical health of our future generations.”

Posted on: 18/04/2017 UTC+08:00


News

Medical rubber glove manufacturer Hartalega Holdings has incorporated a 70% owned subsidiary company in China called Foshan Dynamic.
Singapore-based dental group Unity Denticare is the latest company to sign an MOU with Malaysian online healthcare booking app BookDoc. The company has now pretty much cornered the dental market in Singapore. At the end of March signed an MOU with Q&M Dental Group, which operates the largest network of private dental outlets in the island state.
The majority of bondholders have decided to redeem their paper in Singapore-listed integrated healthcare services and facilities provider International Healthway Corporation.
Leading domestic media organisation Singapore Press Holdings is moving into healthcare with the acquisition of Orange Valley Healthcare from KV Asia Capital for S$164 million (US$118 million). The acquisition will be funded with a mixture of cash and debt.
TalkMed Group, a provider of medical oncology and palliative care health care services, has reported a 1.7% decline in profits for the first quarter of the year to S$8.4 million (US$6 million) on revenues that rose 1.4% to S$16.2 million.
Care home operator Pine Care Group has sold a care home in Kwun Tong, Kowloon, for HK$6.6 million (US$853,000) to Goal Achiever Ventures, a company incorporated in the British Virgin Islands.
Shares in Aoxin Q&M Dental Group (AQMD), a spin off of Singapore’s Q&M Dental Group, jumped 17.5% on their SGX debut today. The company raised S$9.1 million (US$6.5 million) selling 57 million shares at S$0.20 each on the Catalist board. SAC Capital handled the deal.
Wenzhou Kangning Hospital, the largest private psychiatric specialty care service provider in China, has delayed plans to list on the Shanghai Stock Exchange, thanks to difficulties with its lawyers.



Analysis

Jonathan Tan, director of Asia Pacific Risk Centre, explains how an aging population and the rise in non-communicable diseases is threatening the affordability of insurance premiums across the region.
“The Asia Pacific healthcare sector’s growth trajectory will be decidedly positive. The expansion of universal healthcare across the region will boost utilisation of medical services, even as the prevalence of chronic diseases rise in tandem with the shift in lifestyles and an ageing population,” says BMI Research in Singapore in a new report on healthcare in Asia.
After a visit to Myanmar, Jiadi Yu, principal investment officer at the IFC in Hong Kong, is optimistic about the country’s health market.
Amid questions about the direction of the global economy, investors doubled down on healthcare as a safe haven in 2016, driving up both the number and the value of deals, according to Bain & Company’s sixth Global Healthcare Private Equity and Corporate M&A Report.
Susann Roth, senior social development specialist, Asian Development Bank, explains how Vietnam is seizing the opportunity of digital health.
The Commonwealth Scientific and Industrial Research Organisation’s new medical technologies and pharmaceuticals roadmap sets out a path for how Australia could become an important player in medical technologies and pharmaceuticals, which is expected to grow to almost A$3 trillion (US$2.3 trillion) globally by 2025.
The takeover of Australian private hospital operator Pulse Health by Healthe Care, Australia’s third largest hospital operator has been put on hold for two months. Yesterday Pulse applied to the Supreme Court of New South Wales to delay a scheme meeting planned for Wednesday this week to approve its takeover, until 1 May.
The renounceable non-underwritten 11-for-200 rights issue for SGX-listed private healthcare provider Health Management International (HMI) has received strong interest from investors. It had a 145.7% subscription rate, raising gross proceeds of S$18.5 million (US$13.1 million).
EducationInvestor Global


The Future of Healthcare in Asia

Round table

Download the round table here




Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices